-The Business Standard One correction - and more to come? Several developments in the Supreme Court over illegal mining of iron ore in Karnataka indicate that only the first chapter of a long-running story has been brought to a satisfactory end. The whole story offers a valuable insight into practices of governance and ways of doing business in India. The first chapter began over half a decade ago, with a report by...
More »SEARCH RESULT
The Ghost’s In The Details, Ma’am-Aakar Patel
Arundhati has got it all wrong—the facts speak out against her romantic notions of the tribals’ fight Nirad C. Chaudhary wrote in The Continent of Circe that India’s tribals were mainly found in hill forests. This was because, he reasoned, they had been chased there by the invading Aryans, who displaced them from their river plains. In an essay published in this magazine (Capitalism: A Ghost Story, March 26), Arundhati Roy...
More »Patent to plunder -Amit Sengupta
India's efforts to produce and supply life-saving drugs at affordable prices face challenges from multinational companies trying to “evergreen” their patents. THE average life expectancy across the globe has increased from around 30 years a century ago to over 65 years today. This has been made possible in large part by modern medicine. Never before in history have humans had access to such an array of medicines and devices to...
More »Question of efficacy -Leena Menghaney
The country is clearly shaping its legislation to promote access to medicines by fostering generic production. INDIA'S approach to the revision of its Patents Act in 2005 is a clear example of a country shaping its legislation to promote access to medicines by fostering generic production. Although World Trade Organisation (WTO) rules made it mandatory for India to put in place a patent regime for medicines by 2005, nothing obliges...
More »A welcome first -TK Rajalakshmi
Industry reacts with caution to the grant of a compulsory licence to Natco, but cancer patients welcome it and hope for many more. THE first compulsory licence (CL) issued by the Indian patent office, to the local drug manufacturer Natco Pharma Ltd to sell the generic version of Bayer AG's anti-cancer drug Nexavar, has led to varied reactions. The landmark decision has also raised concerns about the outcome of cases...
More »